Let’s dig into the relative performance of Cigna (NYSE:CI) and its peers as we unravel the now-completed Q4 health insurance ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Cigna looks undervalued at under 10x earnings, with strong growth potential. Evernorth continues to expand, adding to the company’s long-term value. Large stock buybacks are supporting earnings ...

Parnassus Core Equity Fund stated the following regarding The Cigna Group (NYSE:CI) in its Q4 2024 investor letter: “The Cigna Group (NYSE:CI) stock declined amid regulatory concerns around its ...

Cigna delivered a strong Q4 performance, with revenue surging 28.4% year over year to $65.65 billion. This exceeded analyst ...

All but Cigna were among the portfolio's top-10 holdings ... We avoided these benchmark components in Q4, as we did not see compelling value opportunities among these names. Throughout the quarter ...

As the Q4 earnings season comes to a close ... Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see The Cigna... TDOC expects revenues in the ...

Revenue (Q4 2024): $298.4 million, up 11% year-over-year ... Progyny Inc (NASDAQ:PGNY) retained 99% of its clients and expanded its partner network, including adding Cigna as its first national health ...

Cigna reported fourth-quarter 2024 adjusted earnings per share of $6.64, which missed the Zacks Consensus Estimate by 15.2% due to a decline in its overall medical customer base and elevated ...

Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous system, ...